<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2288">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05131373</url>
  </required_header>
  <id_info>
    <org_study_id>ORI-101-PAC</org_study_id>
    <nct_id>NCT05131373</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris</brief_title>
  <acronym>OREA</acronym>
  <official_title>A Phase I, Multi-center, Double-blind, Randomized, Dose Escalating, Parallel Group, Placebo-controlled Safety, Tolerability and Immunogenicity Study of ORI-A-ce001 for the Treatment of Facial Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Origimm Biotechnology GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Origimm Biotechnology GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial investigates the safety and tolerability of three different doses and two types of&#xD;
      administration routes of a C. acnes vaccine (ORI-A-ce001) in subjects with acne vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acne vulgaris, or acne, is one of the most prevalent diseases worldwide, with skin conditions&#xD;
      being one of the top causes of years lived with disability and non-fatal disease burden.&#xD;
      Despite being one of the most prevalent diseases worldwide, the most widely used treatments&#xD;
      in acne have changed little in the past 30 years. To date there is still no effective&#xD;
      treatment that can prevent and cure this disease. The currently available acne therapies have&#xD;
      been discovered several decades ago, and almost no progress was made in developments of&#xD;
      novel, breakthrough treatment approaches.&#xD;
&#xD;
      The present randomized, placebo-controlled, dose escalation, Phase 1 trial (ORI-101-PAC) is&#xD;
      intended to investigate the safety, tolerability and immunogenicity of an acne vulgaris&#xD;
      vaccine (ORI-A-ce001) at three different dose levels and two different administration routes&#xD;
      in subjects aged ≥18 years suffering from moderate facial acne vulgaris who are otherwise&#xD;
      healthy. The present study will also generate preliminary data on efficacy (inflammatory and&#xD;
      non-inflammatory acne lesion counts, acne severity), immunogenicity and functionality of the&#xD;
      vaccine, as well as a possible impact on skin microbiome composition. Control groups&#xD;
      receiving placebo are included. Data from this trial will be used to inform the design of&#xD;
      future studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2021</start_date>
  <completion_date type="Anticipated">February 13, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 13, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Sequential cohorts (dose escalation, different administration routes)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of solicited and unsolicited local and/or systemic adverse events (AEs)</measure>
    <time_frame>7 days following each vaccination</time_frame>
    <description>Number of participants with AEs as assessed by electronic diary (eDiary) and/or PI assessment, and compared to placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs and serious adverse events (SAEs)</measure>
    <time_frame>through study completion, an average of 9 months</time_frame>
    <description>Incidence of AEs and SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with AEs or SAEs as assessed by physical examination</measure>
    <time_frame>through study completion, an average of 9 months</time_frame>
    <description>Number of participants with AEs or SAEs as assessed by physical examination, vital signs, local skin responses, as assessed by treatment arm (vaccine and placebo)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from the baseline in laboratory data</measure>
    <time_frame>through study completion, an average of 9 months</time_frame>
    <description>Clinically significant change from the baseline in laboratory data as compared to placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from the baseline in vital signs</measure>
    <time_frame>through study completion, an average of 9 months</time_frame>
    <description>Clinically significant change from the baseline in vital signs as compared to placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from the baseline in ECG</measure>
    <time_frame>Weeks 0 and 36</time_frame>
    <description>Clinically significant change from the baseline in electrocardiogram (ECG) as compared to placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from the baseline in physical examination</measure>
    <time_frame>through study completion, an average of 9 months</time_frame>
    <description>Clinically significant change from the baseline in physical examination, as compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity assessment</measure>
    <time_frame>Weeks 0, 4, 8, 12, 16, 24 and 36</time_frame>
    <description>The amount of vaccine-antigen-specific serum antibody titers (IgG), measured by ELISA, compared to placebo and compared among different treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory lesion counts</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32 and 36</time_frame>
    <description>Absolute and percentage change from Baseline in the number of inflammatory acne lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in non-inflammatory lesion counts</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32 and 36</time_frame>
    <description>Absolute and percentage change from Baseline in the number of non-inflammatory acne lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's global assessment (IGA) - change from Baseline</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32 and 36</time_frame>
    <description>Absolute change in IGA score from Baseline [scores: 0-4; 0=clear, 4=severe]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's global assessment (IGA) - percentage of subjects with improvement</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32 and 36</time_frame>
    <description>Percentage of subjects with at least one-grade improvement in their Baseline IGA score (assessment of mild, clear or almost clear) [scores: 0-4; 0=clear, 4=severe]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of subjects' treatment acceptability</measure>
    <time_frame>Week 16</time_frame>
    <description>Treatment acceptability, as assessed by the pre-defined questionnaire</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C. acnes vaccine in adjuvanted formulation will be administered in double-blind fashion in 3 single increasing doses given i.m.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in adjuvanted formulation will be administered in double-blind fashion in single i.m. injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C. acnes vaccine in non-adjuvanted formulation will be administered in double-blind fashion and as a single i.m. or i.d. injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in non-adjuvanted formulation will be administered in double-blind fashion and as a single i.m. or i.d. injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORG101 - Experimental 1</intervention_name>
    <description>C. acnes vaccine Injection, 25 mcg, 75 mcg, 225 mcg, 4 single i.m. injections given in monthly intervals</description>
    <arm_group_label>Experimental 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORG101PL - Placebo 1</intervention_name>
    <description>Injection, sterile aqueous solution of aluminium hydroxide, 4 single i.m. injections given in monthly intervals</description>
    <arm_group_label>Placebo 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORG102 - Experimental 2</intervention_name>
    <description>C. acnes vaccine Injection, 225 mcg, 4 single i.m. or. i.d. injections given in monthly intervals</description>
    <arm_group_label>Experimental 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORG102PL - Placebo 2</intervention_name>
    <description>Injection, phosphate-buffered saline, 4 single i.m. or i.d. injections given in monthly intervals</description>
    <arm_group_label>Placebo 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subject aged ≥18 years at the time of informed consent signature&#xD;
&#xD;
          -  Female subjects of childbearing potential must have a negative serum or urine&#xD;
             pregnancy test at Screening and before vaccination and must be willing to practice a&#xD;
             highly effective method of contraception during the study&#xD;
&#xD;
          -  Subject with a clinical diagnosis of moderate facial acne vulgaris (grade 3 on a&#xD;
             5-grade IGA scale) at Baseline Visit&#xD;
&#xD;
          -  Subject must have a maximum of 40 non-inflammatory acne lesions (open and closed&#xD;
             comedones) and between a minimum of 20 and a maximum of 70 inflammatory acne lesions&#xD;
             (papules and pustules) and a maximum of 1 nodulocystic lesion (nodules and cysts) on&#xD;
             the face (e.g., forehead, nose, cheeks, chin, upper lip) at Baseline Visit&#xD;
&#xD;
          -  Negative Covid test at Baseline Visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject who is pregnant, lactating or is planning a pregnancy during the study period&#xD;
&#xD;
          -  Subject who has active nodulocystic acne, acne conglobata, acne fulminans, secondary&#xD;
             acne or other forms of acne&#xD;
&#xD;
          -  Subject who has more than one facial nodules/cysts (where nodule/cyst is defined as an&#xD;
             inflammatory lesion greater than or equal to 0.5 cm in size with or without cystic&#xD;
             changes)&#xD;
&#xD;
          -  Subject who has any skin pathology or condition that, in the Investigator's opinion,&#xD;
             could interfere with the evaluation of the Investigational Medicinal Product (IMP) or&#xD;
             requires use of interfering topical, systemic, or surgical therapy&#xD;
&#xD;
          -  Subject with excessive facial hair, facial skin disorders, skin reactions that may&#xD;
             interfere with the study assessments in the Investigator's opinion or skin infection&#xD;
&#xD;
          -  History of Guillain-Barré-Syndrome&#xD;
&#xD;
          -  Subject who has used any acne-affecting treatment without an appropriate washout&#xD;
             period&#xD;
&#xD;
          -  Subject who receives active or passive vaccination within 30 days prior to Baseline&#xD;
             Visit Initiation or change of hormonal contraceptive use within 12 weeks prior to&#xD;
             Screening Visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zrinka Ivezic-Schoenfeld, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Origimm Biotechnology GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ira G Federspiel, PhD</last_name>
    <phone>+436763699216</phone>
    <email>ifederspiel@origimm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitäts-Hautklinik Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Hahn, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <state>Hesse</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Pinter, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fachklinik Bad Bentheim</name>
      <address>
        <city>Bad Bentheim</city>
        <state>North Rhine-Westphalia</state>
        <zip>48455</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Athanasios Tsianakas, PD Dr.med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum der Ruhr-Universitaet Bochum (UKRUB)</name>
      <address>
        <city>Bochum</city>
        <state>North Rhine-Westphalia</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Falk Bechara, Prof.Dr.med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CentroDerm</name>
      <address>
        <city>Wuppertal</city>
        <state>North Rhine-Westphalia</state>
        <zip>42287</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Dirschka, Prof.Dr.med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UKSH, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diamant Thaci, Prof.Dr.med.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.origimm.com/</url>
    <description>ORIGIMM Biotechnology</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 11, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acne vulgaris</keyword>
  <keyword>C. acnes</keyword>
  <keyword>vaccine</keyword>
  <keyword>dose escalation</keyword>
  <keyword>first in human</keyword>
  <keyword>FIH</keyword>
  <keyword>skin microbiome</keyword>
  <keyword>placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

